Targeted Therapies in Endometrial Cancer

Endometrial cancer is the most common gential cancer in developed world. It is generally diagnosed in early stage and it has a favorable prognosis. However, advanced staged disease and recurrences are difficult to manage. There are some common genetic alterations related to endometrial carcinogenesis in similar fashion to other cancers. Personalized medicine, which means selection of best suited treatment for an individual, has gain attention in clinical care of patients in recent years. Targeted therapies were developed as a part of personalized or "tailored" medicine and specifically acts on a target or biologic pathway. There are quite a number of molecular atteration points in endometrial cancer such as PTEN tumor suppressor genes. DNA mismatch repair genes, P13K/AKT/mTOR pathway and p53 oncogene which all might be potential candidates for tailored targeted therapy. In recent years targeted therapies has clinical application in ovarian cancer patients and in near future with the advent of new agents these "tailored" drugs will be in market for routine clinical practice in endometrial cancer patients in primary disease and recurrences as well.